Tag: safiglipron
-
REMODEL’s Primary Kidney-Imaging Endpoints Were Null. The “Mechanism” Story Comes From Secondary and Exploratory Layers Instead
Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice. This post covers two peer-reviewed randomized trials of incretin-axis drugs, both industry-sponsored. Every number below is attributed to its source tier — peer-reviewed full text, a public trial registry, or a sponsor statistical…
